Drs. Kato and Kurzrock discuss the potential reasons why some cancer patients experience hyperprogression of disease while on immunotherapy treatment.
Shumei Kato, MD
Advertisement
Articles by Shumei Kato, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Toxicity From CD19, BCMA Therapy May Inform B-Cell Malignancy Surveillance
2
Sac-TMT Significantly Improves PFS/OS in Pretreated Endometrial Cancer
3
Nogapendekin Alfa Plus BCG Exhibits Efficacy Advantage in NMIBC In Situ
4
Fianlimab Combo Does Not Significantly Improve PFS in Advanced Melanoma
5